Meeting
2019 Gastrointestinal Cancers Symposium
CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.
Authors
Steven Allen Buechler
University of Notre Dame, Notre Dame, IN
Steven Allen Buechler , Yesim Gokmen-Polar , Sunil S. Badve
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 598)
DOI
10.1200/JCO.2019.37.4_suppl.598
Abstract #
598
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu
Poster
2013 ASCO Annual Meeting
Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
First Author: Henry Li
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.
First Author: Melanie Nicole Woods